1-Tert-butyl-4-ethoxy-1,4lambda5-azaphosphinane 4-oxide

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-Tert-butyl-4-ethoxy-1,4lambda5-azaphosphinane 4-oxide
• 英文别名: 1-tert-butyl-4-ethoxy-1,4λ5-azaphosphinane 4-oxide
• 化学式: C₁₀H₂₂NO₂P
• 分子量: 219.26
• InChiKey: FCBJVAATRDCVTE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE
  申请人：NewGen Therapeutics, Inc.

  公开号：US20140221314A1

  公开（公告）日：2014-08-07

  The invention provides for compositions comprising phosphorous containing tricyclic compounds, including phthalazin-1(2H)-one derivatives. The compounds are potent inhibitors of the enzyme poly(ADP-ribose)polymerase (PARP), particularly PARP-1 and potentially PARP-2. The also show good cellular activity in inhibiting poly(ADP-ribose) oligomer formation. The compounds may be useful as mono-therapy or in combination with other therapeutic agents in the treatment conditions where PARP is implicated, such as cancer, inflammatory diseases and ischemic conditions. Thus, also provided are methods for the treatment of a condition where PARP is implicated comprising administering to an effective amount of a compound of the invention to an individual in need thereof.

  本发明提供了包含含磷三环化合物的组合物，包括邻苯二酮-1(2H)-酮衍生物。这些化合物是聚(ADP-核糖)聚合酶(PARP)的有效抑制剂，特别是PARP-1和潜在的PARP-2。它们还表现出良好的细胞活性，能够抑制聚(ADP-核糖)寡聚体形成。这些化合物可用作单一治疗或与其他治疗药物联合使用，治疗PARP参与的疾病，如癌症、炎症性疾病和缺血性疾病。因此，本发明还提供了一种治疗PARP参与的疾病的方法，包括向需要的个体施用本发明化合物的有效量。
• Tricyclic inhibitors of poly(ADP-ribose)polymerase
  申请人：Rakovina Therapeutics Inc.

  公开号：US11248013B2

  公开（公告）日：2022-02-15

  The invention provides for compositions comprising phosphorous containing tricyclic compounds, including phthalazin-1(2H)-one derivatives. The compounds are potent inhibitors of the enzyme poly(ADP-ribose)polymerase (PARP), particularly PARP-1 and potentially PARP-2. The also show good cellular activity in inhibiting poly(ADP-ribose) oligomer formation. The compounds may be useful as mono-therapy or in combination with other therapeutic agents in the treatment conditions where PARP is implicated, such as cancer, inflammatory diseases and ischemic conditions. Thus, also provided are methods for the treatment of a condition where PARP is implicated comprising administering to an effective amount of a compound of the invention to an individual in need thereof.

  本发明提供了包含含磷三环化合物（包括酞嗪-1(2H)-酮衍生物）的组合物。这些化合物是聚（ADP-核糖）聚合酶（PARP）的强效抑制剂，尤其是 PARP-1，也可能是 PARP-2。这些化合物在抑制聚（ADP-核糖）寡聚体形成方面也显示出良好的细胞活性。在治疗与 PARP 有关的疾病（如癌症、炎症性疾病和缺血性疾病）时，这些化合物可作为单一疗法或与其他治疗剂联合使用。因此，还提供了治疗与 PARP 有关的病症的方法，包括向有需要的个体施用有效量的本发明化合物。